Immunotherapy is a treatment which uses particular parts of person’s immune organism to fight against cancer. Immune system is a collection of special cells, organs and substance which protect us from diseases and infections. Immune cells and the substances that make set out through your body to shield it from germs that cause diseases. The immune system monitors the majority of the substances typically found in the body. Any new substance that the immune system doesn’t perceive raises an alert, creating the resistant framework to assault it. Cancer immunotherapy is a medicine that outfit and upgrade the inborn forces of the immune system to battle tumor which represents the most encouraging new disease treatment approach since the improvement of the principal chemotherapies in the late 1940s.
How Big is the Cancer Immunotherapy Market?
The cancer immunotherapy market is expected to Growing at a CAGR of more than 14% in the given forecast period.
The major driving factors of cancer immunotherapy market are as follows:
Expansion of bioinformatics tools will enhance drug development procedure
Growth in adoption of immunotherapy above other treatment alternatives
Increase in incidence rate of cancer worldwide
The restraining factors of cancer immunotherapy market are as follows:
Treatment cost is high
The cancer immunotherapy market is segmented on the lines of its type, application, end user and regional. Based on type segmentation it covers immunomodulators, checkpoint inhibitors, cancer vaccines and monoclonal antibodies. Under application segmentation it covers melanoma, colorectal cancer, prostate cancer, head and neck cancer, breast cancer and lung cancer. The cancer immunotherapy market is segmented on the lines of its end user like clinics and others hospitals.The cancer immunotherapy marketis geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for cancer immunotherapy and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Discovering of new market opportunities and targeted promotional plans for cancer immunotherapy.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for Cancer Immunotherapy market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).. Company profile includes assign such as company summary, financial summary,business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Cancer Immunotherapy Market has been segmented as below:
By Type Segment Analysis
Immunomodulators
Checkpoint inhibitors
Cancer vaccines
Monoclonal antibodies
By Application Analysis
Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
By End-user Analysis
Hospitals
Clinics and others
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all cancer immunotherapy treatment globally.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of cancer immunotherapy data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
Drug Discovery Technologies market
Drug Eluting Balloons （DEB） market
Drug of Abuse (DOA) Testing Consumables Market
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Cancer Immunotherapy Market Size Estimation
2.2 Cancer Immunotherapy Market Breakdown and Data Triangulation
2.3 Cancer Immunotherapy Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.4 Assumptions for the Study
3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
4 Premium Insights
4.1 Lucrative Opportunities in the Cancer Immunotherapy Market
5 Market Overview
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Rise in Incidence Rate of Cancer Worldwide
5.1.1.2 Increase in Adoption of Immunotherapy Over Other Treatment Options
5.1.1.3 Development of Bioinformatics Tools are Enhancing Drug Development Process
5.1.2 Restraints
5.1.2.1 High Cost of Treatment
5.1.3 Opportunities
5.1.3.1 Increase in Clinical Trials Against Several Types of Cancers in Immunotherapy
5.1.3.2 High Growth Projections in the Developing Countries
5.1.4 Challenges
5.1.4.1 Availability of Limited Funds to Initiate Clinical Trials
5.1.4.2 Complexity of Cancer May Limit the Immune Response
5.2 Overview of Global Cancer Immunotherapy Funding
6 Industry Trends
6.1 Global Trends in Cancer Immunotherapy Market
6.1.1 Opdivo (Niolumab) and Keytruda (Pembrolizumab) Fda Approval in U.S. Increases Hope Amongst Lung Cancer Patients
6.1.2 Combination Immunotherapy Potential Way to Treat Melanoma
6.1.3 U.S. Cancer Immunotherapy Research Community Builds Hope to Combat Cancer By 2020
6.1.4 U.K. Scientists Project A Change in the Means of Treatment for Cancer With Quality Therapies
6.1.5 World is Moving Toward Personalized Immunotherapy
6.1.6 A Combination of Modern Immunotherapy and Traditional Chinese Medicines Continues to Increase Survival Rate of Patients in China
6.2 Pricing Variations in Global Cancer Immunotherapy Market
6.3 Small Players Getting Together to Make Long Term Impact in Cancer Immunotherapy Market
6.4 Attractions for Pharmaceutical Industry
6.5 Heat Map for Variations in Cancer Immunotherapy for Different Types of Cancers
6.5.1 Breast Cancer
6.5.2 Lung Cancer
6.5.3 Multiple Myeloma
6.5.4 Lymphoma
7 Cancer Immunotherapy Market, By Product Type
7.1 Introduction
7.2 Monoclonal Antibodies
7.2.1 Naked Monoclonal Antibodies
7.2.2 Conjugated Monoclonal Antibodies
7.2.3 Bispecific Monoclonal Antibodies
7.3 Vaccines
7.3.1 Prophylactic Vaccines
7.3.2 Therapeutic Vaccines
7.4 Check Point Inhibitors
7.4.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.4.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.5.2 Dendritic Cells
7.6 Immunomodulators
7.6.1 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF)
7.6.2 Interferons (IFN)
7.6.3 Interleukins (IL)
7.6.4 Oncolytic Virus
7.6.4.1 Immunotherapy
7.6.4.1 Immunity as an Obstacle
7.6.4.2 Immunity as an Ally
7.6.4.3 Approved Products & Clinical Trails
8 Cancer Immunotherapy Market, By Application
8.1 Introduction
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Multiple Myeloma
8.5 Colorectal Cancer
8.6 Head & Neck Cancer
8.7 Prostate Cancer
8.8 Melanoma
8.9 Other Cancer Types
9 Cancer Immunotherapy Market, By End User
9.1 Introduction
9.2 Hospital
9.3 Clinics and Others
10 Cancer Immunotherapy Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World (RoW)
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Approvals
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Acquisitions
11.3.4 Expansions
11.3.5 Other Developments
12 Company Profile
12.1 Amgen Inc.
12.2 Astrazeneca
12.3 Bayer AG
12.4 Bristol-Myers Squibb
12.5 Eli Lilly and Company
12.6 Janssen Global Services, LLC (Johnson and Johnson)
12.7 Merck
12.8 Novartis
12.9 Pfizer
12.10 F. Hoffmann-LA Roche Ltd
The Cancer Immunotherapy Market has been segmented as below:
By Type Segment Analysis
Immunomodulators
Checkpoint inhibitors
Cancer vaccines
Monoclonal antibodies
By Application Analysis
Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
By End-user Analysis
Hospitals
Clinics and others
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
SUBSCRIBE TO OUR NEWSLETTERS
